Prof. Peter Schmid, Consultant Medical Oncologist

Prof. Peter Schmid

Consultant Medical Oncologist

Book online
|

Prof. Peter Schmid MD PhD FRCP

Consultant Medical Oncologist

MD PhD FRCP

Prof. Peter Schmid

Consultant Medical Oncologist MD PhD FRCP

Book online
|
MD PhD FRCP
HCA-Healthcare-UK

Areas of expertise

  • Breast oncology
  • Dealing with early breast lumps
  • Lung cancer
  • Immunotherapy
  • Triple negative breast cancer
HCA-Healthcare-UK

Recommendations for Prof. Schmid

These recommendations are for information purposes only. Doctors providing recommendations do so in good faith and are not responsible for clinical outcomes.

Recommended by:

  • byMr Neill Patani, Consultant Oncoplastic & Reconstructive Breast Surgeon

    Prof. Peter Schmid is an expert medical oncologist with a particular interest in clinical trials and immunotherapy for some of the most aggressive types of triple-negative breast cancer. He is key member of our multi-disciplinary team at the London Breast Institute.

  • byMr Neill Patani, Consultant Oncoplastic & Reconstructive Breast Surgeon

    Prof. Peter Schmid is an expert medical oncologist with a particular interest in clinical trials and immunotherapy for some of the most aggressive types of triple-negative breast cancer. He is key member of our multi-disciplinary team at the London Breast Institute.

  • Address

    • LOC at Chelsea

      102 Sydney Street, Chelsea, London, SW3 6NJ

    • LOC - Leaders in Oncology Care

      95-97 Harley Street, London, W1G 6AF

    • London Bridge Hospital

      27 Tooley Street, London, SE1 2PR

    • The Wellington Hospital

      Wellington Place, St John's Wood, London, NW8 9LE

    About Prof. Peter Schmid

    GMC number: 6111181

    Year qualified: 1997

    Place of primary qualification: Technische Universität München

    Professor Peter Schmid is an internationally renowned breast cancer oncologist. He serves as the clinical director of the Breast Cancer Centre at St. Bartholomew’s Hospital in London and holds the position of Chair in Cancer Medicine at Barts Cancer Institute, Queen Mary University London.

    Professor Schmid’s work focuses on integrating novel therapies, grounded in the biology of cancer, with high-quality care for women with breast cancer. His areas of expertise include the diagnosis, treatment, and optimal recovery of breast cancer patients. He has a particular interest in triple-negative breast cancer, young women with breast cancer, pregnancy-associated breast cancer, and fertility-related issues.

    Professor Schmid is dedicated to patient-centered, holistic care. He tailors treatments to individual patients, considering biological factors, personal preferences, and continuous review of care outcomes. He operates within a multidisciplinary team, ensuring comprehensive support for patients, including breast care nurse assistance.

    Professor Schmid is also passionate about patient-doctor communication. He has led a training program for oncologists and oncology nurses for many years, emphasizing the importance of effective communication in patient care. His research aims to improve the treatment of women with breast cancer by developing more effective and less toxic therapies.

    In his role, Professor Schmid is committed to advancing the field of breast cancer treatment and ensuring the best possible outcomes for his patients.

    Areas of expertise

    • Breast oncology
    • Dealing with early breast lumps
    • Lung cancer
    • Immunotherapy
    • Triple negative breast cancer

    Professional memberships

    Royal College of Physicians
    General Medical Council

    Articles by Prof. Peter Schmid

    C45the role of ribociclib in hormone receptor-positive (hr+), human epidermal growth factor receptor 2-negative (her2–) early breast cancer: the earlee adjuvant clinical trials program

    Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (fergi): a randomised, double-blind, placebo-controlled, phase 2 trial

    Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers

    Phlda1 mediates drug resistance in receptor tyrosine kinase-driven cancer